Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease in the United States. The company's product candidates comprise SYMJEPI epinephrine pre-filled syringe injectable products for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products for the treatment of asthma; and naloxone injection for the treatment of opioid overdose. It also offers APC400, a tempol gel use of reducing radiation dermatitis in patients undergoing treatment for cancer; and APC410 for the treatment of respiratory diseases, including asthma, respiratory syncytial virus, influenza, and COVID-19. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, and injectables; and veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation was founded in 2006 and is headquartered in San Diego, California.
P/E ratio for Adamis Pharmaceuticals Corporation (ADMP)
P/E ratio as of 2022: -0.97
According to Adamis Pharmaceuticals Corporation's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.97. At the end of 2021 the company had a P/E ratio of -2.52.
P/E ratio history for Adamis Pharmaceuticals Corporation from 1993 to 2022
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2022 | -0.97 |
| 2021 | -2.52 |
| 2020 | -0.76 |
| 2019 | -1.27 |
| 2018 | -2.25 |
| 2017 | -4.88 |
| 2016 | -2.84 |
| 2015 | -5.28 |
| 2014 | -5.73 |
| 2013 | -9.28 |
| 2012 | -4.19 |
| 2011 | -1.70 |
| 2010 | -0.92 |
| 2009 | -6.10 |
| 2008 | -6.76 |
| 2007 | -6.92 |
| 2006 | 0.17 |
| 2005 | -3.19 |
| 2004 | -2.24 |
| 2003 | -4.57 |
| 2002 | -5.98 |
| 2001 | -6.83 |
| 2000 | -6.45 |
| 1999 | -4.36 |
| 1998 | -4.81 |
| 1997 | -10.72 |
| 1996 | -6.82 |
| 1995 | -2.85 |
| 1994 | -4.88 |
| 1993 | -5.08 |